Medyra Pharmaceutica

  In recent years, India has seen a significant rise in cancer cases, driving demand for high-quality, affordable oncology medicines . Delhi NCR has emerged as a key hub for oncology medicine manufacturers in Delhi , offering advanced anti-cancer drugs, injections, tablets, and generics. These anti cancer drug manufacturers in Delhi focus on WHO-GMP certified production, innovative formulations, and export-quality standards, making them trusted partners for hospitals, distributors, and PCD franchise seekers. Whether you're searching for top oncology pharma companies in Delhi NCR , reliable cancer medicine suppliers in Delhi , or oncology injections manufacturers in Delhi , this guide highlights the leading players revolutionizing cancer care in 2026. Why Delhi NCR Excels in Oncology Pharma Manufacturing Delhi's strategic location, skilled workforce, and proximity to regulatory bodies make it ideal for pharmaceutical innovation. Many oncology drug exporters in Delhi sup...

  The growing global burden of cancer has significantly increased the demand for high-quality, affordable oncology medicines. India has emerged as a key player in this space, with several pharmaceutical hubs contributing to cancer drug production. Among them, Delhi holds a strategic position due to its advanced infrastructure, regulatory ecosystem, and proximity to major healthcare and research institutions. As a result, oncology medicine manufacturers in Delhi, India play a vital role in strengthening both domestic and international cancer care supply chains. India’s Role in Oncology Drug Manufacturing India is widely recognized as the “pharmacy of the world,” supplying cost-effective and quality-assured medicines to over 200 countries. In oncology, Indian manufacturers produce a wide range of products including oral solid dosage forms, injectables, cytotoxic drugs, and targeted cancer therapies. Strict adherence to global quality standards such as WHO-GMP, ISO certifications...

  India has emerged as a global powerhouse in oncology pharmaceutical manufacturing , with the market projected to grow by USD 2.02 billion at a CAGR of 19.8% between 2024 and 2029. This remarkable growth is driven by cost-effective manufacturing, cutting-edge research capabilities, and an extensive export network reaching over 150 countries worldwide. Market Overview and Growth Statistics The Indian pharmaceutical industry ranks as the third-largest globally by volume and seventh by value, contributing over 20% of global generic drug exports. In oncology specifically: Market Size Growth : USD 2.02 billion expansion expected by 2029 Growth Rate : 19.8% CAGR (2024-2029) Export Reach : 150+ countries Cost Advantage : Up to 80% lower than developed nations Export Value : USD 3.2 billion in oncology drugs (2023) Key Market Drivers 1. Increasing Cancer Prevalence Estimated 1.6 million new cancer cases in India by 2025 Growing ...

  India has emerged as a global powerhouse for high-quality oncology medicines, especially Paclitaxel. From strong manufacturing expertise to strict GMP compliance, Indian companies now supply Paclitaxel injections and API to more than 65+ countries. This guide helps buyers, hospitals, distributors, and tender agencies understand India’s Paclitaxel landscape and how to choose a trusted manufacturer.   What is Paclitaxel? (Quick Overview) Paclitaxel is a widely used chemotherapy injection for treating breast cancer, ovarian cancer, lung cancer, cervical cancer, and AIDS-related Kaposi Sarcoma. In India, it is available in multiple strengths — 30 mg, 100 mg, 300mg and 260 mg — typically supplied in multi-dose vials under strict cytotoxic handling protocols.   Why India is a Global Hub for Paclitaxel Manufacturing India's oncology ecosystem offers unmatched advantages: WHO-GMP & ISO-certified facilities Competitive pricing due to optimized...